Immunic completes enrollment of its phase 2 calliper trial of vidofludimus calcium in progressive multiple sclerosis

– unblinded interim biomarker analysis expected in the fall of 2023 – –  full data readout expected in april 2025 – new york , aug. 17, 2023 /prnewswire/ -- immunic, inc. (nasdaq: imux), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced the completion of enrollment of its phase 2 calliper trial of lead asset, vidofludimus calcium (imu-838), in patients with progressive multiple sclerosis (pms). in total, 467 patients with primary pms, or active or non-active secondary pms have been randomized to either 45mg of vidofludimus calcium or placebo.
IMUX Ratings Summary
IMUX Quant Ranking